☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Eli Lilly
Eli Lilly Reports Detailed Results from the P-III (QWINT-2 & 5) Trials of Insulin Efsitora Alfa (Efsitora) for Type 1 & 2 Diabetes...
September 11, 2024
Eli Lilly Reports Topline Results from P-III (QWINT-1 and QWINT-3) Studies of Efsitora Alfa (Efsitora) for Type 2 Diabetes
September 6, 2024
PharmaShots Weekly Snapshots (August 20 – August 23, 2024)
August 23, 2024
Eli Lilly Reports Topline Data from P-III (SURMOUNT-1) Trial of Tirzepatide to Treat Type 2 Diabetes
August 21, 2024
Eli Lilly Reports the P-III (SUMMIT) Trial Data of Tirzepatide to Treat Heart Failure with Preserved Ejection Fraction and Obesity
August 2, 2024
Eli Lilly to Acquire Morphic Holdings for an Aggregate of ~$3.2B
July 8, 2024
Load more...
Back to Home